Literature DB >> 22932274

A potentially misleading finding at somatostatin receptor scintigraphy: focal pulmonary areas of intense accumulation without computed tomography-detectable lung lesions.

F Minutoli, A Herberg, A Sindoni, D Cardile, M Cucinotta, S Baldari.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22932274     DOI： 10.1007/BF03345801

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  5 in total

1.  Positive In-111 pentetreotide scintigraphy: pulmonary hamartoma.

Authors:  R J Klecker; A M Cioc; R V Pozderac
Journal:  Clin Nucl Med       Date:  2001-03       Impact factor: 7.794

2.  Intense octreotide activity in a thrombus.

Authors:  Sabah Servaes; Ghassan El-Haddad; Hongming Zhuang
Journal:  Clin Nucl Med       Date:  2008-02       Impact factor: 7.794

3.  Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas.

Authors:  F Gibril; J C Reynolds; C C Chen; F Yu; S U Goebel; J Serrano; J L Doppman; R T Jensen
Journal:  J Nucl Med       Date:  1999-04       Impact factor: 10.057

4.  111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Valentina Ambrosini; Cumali Aktolun; Richard P Baum; Angelica Bishof-Delaloye; Silvana Del Vecchio; Lorenzo Maffioli; Luc Mortelmans; Wim Oyen; Giovanna Pepe; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07       Impact factor: 9.236

Review 5.  The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology.

Authors:  G L Cascini; V Cuccurullo; L Mansi
Journal:  Q J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 2.346
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.